Acrobiosystems Co.,Ltd.

SZSE:301080 Stock Report

Market Cap: CN¥6.4b

AcrobiosystemsLtd Past Earnings Performance

Past criteria checks 3/6

AcrobiosystemsLtd's earnings have been declining at an average annual rate of -3.5%, while the Biotechs industry saw earnings declining at 6.4% annually. Revenues have been growing at an average rate of 19.2% per year. AcrobiosystemsLtd's return on equity is 6.3%, and it has net margins of 19.3%.

Key information

-3.55%

Earnings growth rate

-9.06%

EPS growth rate

Biotechs Industry Growth11.29%
Revenue growth rate19.21%
Return on equity6.32%
Net Margin19.30%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article • Feb 12

Acrobiosystems Co.,Ltd. (SZSE:301080) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Acrobiosystems Co.,Ltd. ( SZSE:301080 ) shareholders have had their patience rewarded with a 26% share price jump in...
Analysis Article • Nov 06

AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think

A lackluster earnings announcement from Acrobiosystems Co.,Ltd. ( SZSE:301080 ) last week didn't sink the stock price...
Analysis Article • Oct 01

Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 27%

Acrobiosystems Co.,Ltd. ( SZSE:301080 ) shares have had a really impressive month, gaining 27% after a shaky period...
Analysis Article • Jul 15

Why We're Not Concerned About Acrobiosystems Co.,Ltd.'s (SZSE:301080) Share Price

There wouldn't be many who think Acrobiosystems Co.,Ltd.'s ( SZSE:301080 ) price-to-earnings (or "P/E") ratio of 30.8x...
Analysis Article • May 02

AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear

Shareholders didn't appear too concerned by Acrobiosystems Co.,Ltd.'s ( SZSE:301080 ) weak earnings. Our analysis...

Revenue & Expenses Breakdown

How AcrobiosystemsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:301080 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 26887171412185
31 Dec 25838166392182
30 Sep 25795173366176
30 Jun 25733151353174
31 Mar 25686134335167
31 Dec 24645124323162
30 Sep 24595109302150
30 Jun 24575119287140
31 Mar 24553139272130
31 Dec 23544154255122
30 Sep 23534166242119
30 Jun 23514186227123
31 Mar 23497195204120
01 Jan 23474204186112
30 Sep 22461219169107
30 Jun 2243821114684
31 Mar 2241018713170
01 Jan 2238517411760
30 Sep 213511598749
30 Jun 213221467344
31 Mar 212861356437
31 Dec 202461165731
31 Dec 19103115720
31 Dec 1870113417
31 Dec 174772510

Quality Earnings: 301080 has high quality earnings.

Growing Profit Margin: 301080's current net profit margins (19.3%) are lower than last year (19.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 301080's earnings have declined by 3.5% per year over the past 5 years.

Accelerating Growth: 301080's earnings growth over the past year (28%) exceeds its 5-year average (-3.5% per year).

Earnings vs Industry: 301080 earnings growth over the past year (28%) exceeded the Biotechs industry -6.1%.

Return on Equity

High ROE: 301080's Return on Equity (6.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/07 00:28
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acrobiosystems Co.,Ltd. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Shiyu ChenChina International Capital Corporation Limited
Kai WangCitic Securities Co., Ltd.